Credit Suisse Group reiterated their neutral rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a report issued on Wednesday morning, Briefing.com Automated Import reports.
A number of other research firms also recently issued reports on TEVA. Barclays reaffirmed a hold rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Argus initiated coverage on Ameriprise Financial in a research report on Friday, July 5th. They issued a buy rating on the stock. Mizuho set a $11.00 target price on Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Monday, June 17th. CIBC raised Centerra Gold from a neutral rating to an outperform rating and lifted their target price for the company from C$9.00 to C$10.50 in a research report on Monday, June 3rd. Finally, Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the company a neutral rating in a research report on Tuesday, June 18th. Five research analysts have rated the stock with a sell rating, fifteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of Hold and a consensus target price of $15.83.
Shares of TEVA opened at $9.25 on Wednesday. The company has a market cap of $9.12 billion, a price-to-earnings ratio of 3.30, a price-to-earnings-growth ratio of 1.07 and a beta of 1.62. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62. The company has a fifty day moving average price of $9.13. Teva Pharmaceutical Industries has a 52 week low of $7.96 and a 52 week high of $25.96.
In related news, Director Sol J. Barer purchased 111,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was bought at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now directly owns 115,942 shares in the company, valued at approximately $1,041,159.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares of the company’s stock, valued at approximately $567,105.78. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.
Several hedge funds have recently modified their holdings of TEVA. Cutler Capital Management LLC acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth $2,539,000. Prudential Financial Inc. boosted its position in Teva Pharmaceutical Industries by 105.5% during the 4th quarter. Prudential Financial Inc. now owns 218,134 shares of the company’s stock worth $3,364,000 after acquiring an additional 111,965 shares during the period. Bank of New York Mellon Corp boosted its position in Teva Pharmaceutical Industries by 3.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,975,038 shares of the company’s stock worth $30,454,000 after acquiring an additional 67,168 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Teva Pharmaceutical Industries by 2.0% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 76,187 shares of the company’s stock worth $1,175,000 after acquiring an additional 1,497 shares during the period. Finally, Northern Trust Corp boosted its position in Teva Pharmaceutical Industries by 2.7% during the 4th quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock worth $103,125,000 after acquiring an additional 175,173 shares during the period. Institutional investors own 65.08% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.